BiotechTube

Placebo + Lusutrombopag

Phase 2Terminated
3 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immune Thrombocytopenia (ITP)

Conditions

Immune Thrombocytopenia (ITP)

Trial Timeline

Mar 18, 2010 → Nov 24, 2010

NCT ID
NCT01054443

About Placebo + Lusutrombopag

Placebo + Lusutrombopag is a phase 2 stage product being developed by Shionogi for Immune Thrombocytopenia (ITP). The current trial status is terminated. This product is registered under clinical trial identifier NCT01054443. Target conditions include Immune Thrombocytopenia (ITP).

What happened to similar drugs?

7 of 20 similar drugs in Immune Thrombocytopenia (ITP) were approved

Approved (7) Terminated (2) Active (13)
✅Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved
✅IgPro10CSLApproved
✅Subcutaneous Immune Globulin (Human) (Hizentra)CSLApproved
✅Methylprednisolone + PrednisoloneBiogenApproved
✅Flebogamma 5% DIFGrifolsApproved
✅Asceniv™ADMA BiologicsApproved
✅BivigamADMA BiologicsApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01054443Phase 2Terminated

Competing Products

20 competing products in Immune Thrombocytopenia (ITP)

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + PlaceboEli LillyPhase 1/2
39
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
17
SatralizumabChugai PharmaceuticalPhase 3
47
LusutrombopagShionogiPhase 2
27
RomiplostimKyowa KirinPhase 1/2
32
AMG 531Kyowa KirinPhase 2/3
38
Romiplostim + PlaceboKyowa KirinPhase 3
40
Romiplostim (AMG-531)Kyowa KirinPhase 2
35
Romiplostim and danazolKyowa KirinPhase 2
31
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
29
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
29
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
40
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
29
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
35
HerombopagJiangsu Hengrui MedicinePhase 3
36
Zostavax®MerckPre-clinical
18
Raltegravir + AtazanavirMerckPre-clinical
26
ZostavaxMerckPre-clinical
26
MK-8723 + Matching PlaceboMerckPhase 1
29
Eltrombopag (Revolade®) + standard therapy (without eltrombopag): HD-DXMNovartisPhase 2
35